

Memorandum

To: Members of the ICOC
From: Rosa Canet-Avilés, PhD, Chief Science Officer, Gil Sambrano, PhD., VP Review
Re: FY26/27 Program Guiding Principles & Review Process
Date: March 26, 2026

Table of Contents

Table of Contents	1
Executive Summary.....	2
Summary of Feedback on Preferences.....	2
Transitioning from Preferences to Guiding Principles	2
Program Guiding Principles	3
Proposed Plan to Implement Guiding Principles Across the Application and Review Lifecycle	5
Proposal for DISC4 FY26/27 Funding Area	14
PDEV Cycle Recurrence	15
Requested Action	16
Appendix A. Outcomes of preference scoring from the first cycles of PDEV, CLIN2, and DISC4.....	18
Appendix B. Portfolio composition across Preclinical and Clinical Programs (PDEV, TRAN1, CLIN1, CLIN2).	39
Appendix C. GWG Review Criteria	44
Appendix D. ARS Memo Template	49

Executive Summary

Over the past months, the CIRM team has gathered feedback from Board members, applicants, and reviewers regarding the implementation of program Preferences and their role in application volume control and portfolio steering. This memo reflects that feedback, incorporates early-cycle outcome data from PDEV, CLIN2, and DISC4, and proposes refinements to ensure that CIRM's funding processes remain scientifically rigorous, strategically aligned with the Strategic Allocation Framework (SAF), and operationally sustainable.

At the March 26 ICOC Meeting, we will be asking the ICOC to approve updated concepts for DISC4, PDEV, and CLIN2 to update how CIRM approaches application volume control and portfolio building, and to determine the area of focus for our upcoming DISC4 application cycle. This memo provides the ICOC with a structured review of the Preference-based approach implemented in FY25/26 and a forward-looking proposal to transition to a Guiding Principles-based framework applied consistently across the application and review lifecycle.

We are requesting that the Board:

- **Approve amendments to DISC4, PDEV, and CLIN2 concept plans** (including the transition from Preferences to Guiding Principles and to how they are implemented across the program)
- **Approve the implementation of the GWG selection process for volume control across applicable programs**
- **Approve the DISC4 focus area for FY26/27**
- **Approve a once per year PDEV funding cycle**

Summary of Feedback on Preferences

The ICOC and applicants raised concerns about the use of a point-based application of Preferences to filter the volume of applications prior to full GWG review. Board members expressed discomfort that a threshold of Preference points effectively determined which proposals advanced to scientific merit review. The Board questioned the use of different score weighting mechanisms across the programs and whether these had unintended effects on the selection of projects. In particular, based on applicant feedback, the Board was concerned that the processes excluded entire categories of modalities or diseases areas.

At the same time, there was clear acknowledgment that CIRM cannot fund every scientifically meritorious application and that volume control is necessary in high-demand programs. Board members and applicants understood that preferences were introduced as a process efficiency tool to focus review on applications aligned with strategic priorities. They also recognized that such tools must be adjustable based on outcomes.

Transitioning from Preferences to Guiding Principles

The current DISC4, PDEV and CLIN2 programs are designed to respond to specific recommendations in the Strategic Allocation Framework. Each program has Guiding Principles for what it will fund, which are described in the Background and Objective sections of the Program Concept Plans and Program Announcements. Program Preferences were derived from Guiding Principles and were intended to be transparent and specific in

order to facilitate an objective application volume filtering mechanism for each program. The Program Preferences were thus playing double duty as prioritizing what each program funds and as filtering for application volume control.

The CIRM Team's analysis of Preference-based volume filtering outcomes is detailed in [Appendix A](#). Our conclusions are largely aligned with the board's primary concerns about the Preference-based application volume filtering prior to GWG review. In addition, this Preference-based approach requires continual adjustment to align the portfolio with Guiding Principles. In summary, we concluded that the Preference-based approach is not a sustainable solution for achieving the dual goals of strategic funding prioritization and application volume control.

We are proposing to remove Preferences in favor of consistently applying each program's Guiding Principles across the application lifecycle to ensure that each program funds scientifically meritorious projects that are aligned with its funding priorities.

Today we are presenting the following for ICOC consideration and approval:

1. The nature of the projects we should fund as expressed in program-specific Guiding Principles,
2. Ensuring that the Guiding Principles are applied most effectively throughout the review process, i.e., by the right party with the right information at the right time, and
3. Other updates to the PDEV and DISC4 Programs.

Program Guiding Principles

Guiding Principles are how CIRM translates SAF recommendations into portfolio outcomes. As DISC4, PDEV and CLIN2 programs address different SAF Goals, it follows that these principles are tailored to the specifics of each program (shown below).

Each program's Guiding Principles are embedded within the fabric of the program. They are encompassed within program objectives, the review criteria by which projects are scientifically evaluated, and they inform the recommendations that CIRM teams bring to the ARS to support funding decisions.

Here, we present Guiding Principles for CLIN2, PDEV, and DISC4. [Appendix A](#) and [Appendix B](#) include granular portfolio data (early cycle outcomes and active portfolio distribution) to aid the Board's consideration of Guiding Principles.

CLIN2

The CLIN2 portfolio will:

- Offer transformative impact for patients, meaning therapies that provide significant benefits over existing therapies and those in clinical trials,
- Address known barriers to access of stem cell-based and genetic therapies, and
- Broadly address both prevalent and rare diseases affecting Californians.

PDEV

The PDEV portfolio will:

- Have potential to deliver transformative improvements in patient outcomes by leveraging cutting-edge therapeutic technologies,
- Advance strategies to improve patient access to stem cell-based and genetic therapies, and
- Broadly address both prevalent and rare diseases affecting Californians.

DISC4

The DISC4 portfolio will:

- Create multidisciplinary research approaches that integrate diverse sources of evidence,
- Innovate through collaboration, network synergy, and data leverage, and
- Implement Neuro Task Force & other organizational priorities.

Patient Access Considerations in CLIN2 and PDEV Guiding Principles

During the March 5th 2026 meeting, members of the Science Subcommittee raised important questions about how CIRM approaches what has historically been referred to as “Access and Affordability.” The CIRM team considered those questions and feedback to clarify the PDEV and CLIN2 Guiding Principles. Those clarifications, as presented in the list of Guiding Principles above, reflect the following points:

- CIRM’s goal as a public funder is not only to support the development of promising therapies, but also to help ensure that those therapies can ultimately reach patients in California. Achieving this requires thinking about potential barriers to patient access during the development process. CIRM does not determine the price of therapies and does not control reimbursement decisions. Those decisions are made by developers, healthcare systems, and payers.
- CIRM’s role is to encourage development strategies that make it more likely that a successful therapy can realistically be delivered to patients. Going forward, CIRM will refer to “Patient Access” or “Access Strategies”, rather than “Access and Affordability” in the context of PDEV and CLIN2 programs to clarify this role.
- In practice, this means asking applicants to consider issues that may affect whether patients can access a therapy once it is available. These requirements are incorporated into CIRM programs in ways that are appropriate to the stage of development.

Proposed Plan to Implement Guiding Principles Across the Application and Review Lifecycle

To ensure that Guiding Principles are applied by the right party with the right information and at the right time, we are proposing the following implementation plan:

1. **Volume Control:** A volume control step in which GWG select projects using scientific value criteria defined from Guiding Principles,
2. **Merit Review:** Continued use of GWG review criteria, informed by program objectives and Guiding Principles, and
3. **Funding Decision:** Along with GWG recommendations, continue to provide CIRM team recommendations in which Guiding Principles are assessed through standardized programmatic factors to inform ARS’s funding decisions.

This proposal preserves scientific review of applications and ensures that portfolio decisions are made transparently at the Board level. It also preserves the strategic focus established through the SAF by ensuring that portfolio outcomes help achieve Impact Goals. Each aspect of the above plan is summarized in Table 1 and elaborated in the memo sections below.

Table 1. Summary of Guiding Principles Implementation Plan.

	Volume Control	Merit Review	Funding Decision
Responsible Party	GWG	GWG	ARS
How Guiding Principles Are Applied	Selection Criteria	Review Criteria	Programmatic Factors
What Happens	<ul style="list-style-type: none"> Applications are assigned to GWG members GWG selects and ranks applications 	<ul style="list-style-type: none"> GWG assesses merit based on review criteria 	<ul style="list-style-type: none"> GWG provides recommendation CIRM Team provides recommendation based on Programmatic Factors ARS decides what to fund

1. Guiding Principles in Volume Control

Scientific review of CIRM applications by the Grants Working Group (GWG) is time and resource intensive, effectively limiting the number of applications that can be fully reviewed in a single cycle. It is often the case that the number of applications received in response to a funding opportunity exceed this limit and strategies to

narrow the pool of applications are required. Over CIRM’s history, different strategies have been tested and utilized such as setting limits on the number of applications that CIRM would accept from any given organization; implementing a preliminary application process; or filtering applications through a positive selection process. This challenge is not unique to CIRM, and many funding agencies utilize different strategies to narrow the pool of applications received including NIH, NSF, CPRIT, and others.

The number of applications that are targeted for review by the full GWG (i.e., the number we wish to narrow the pool to) is based on preserving a high level of rigor in performing the evaluations by the 15 appointed scientific members of the working group along with the 7 patient advocate members. The number of available awards and expected success rate may also be considered in determining the number that advances to full review to ensure that the pool is sufficient while allowing for robust time and discussion during the GWG meeting phase.

GWG panels are tailored in their composition to the specific set of applications reviewed to ensure that the expertise is well matched. Recruitment of appropriate reviewers includes identifying specialists that can enhance the expertise of the panel. For CIRM, a complete evaluation may include elements not always present in other funding programs such as elements of population impact and patient access.

Over the last year, CIRM used “pre-submissions” (DISC4 & PDEV) and “qualification” (CLIN2) as methods to control volume that were dependent on the use of strict objective Preference criteria (Table 2). Although these methods proved effective in narrowing the pool, the use of preferences, in particular, has limited advancement of applications based on a set of narrow characteristics rather than on a scientific assessment of the proposals.

Table 2. FY25/26 Volume Control Approaches

	DISC5	DISC4	PDEV	CLIN2
Current Process	Positive Selection	Pre-Submission	Pre-Submission	Qualification
Submission	Full Application	Pre-Submission Form	Pre-Submission Form	Full Application
Selection by	GWG	CIRM	CIRM	CIRM/GWG
Basis for selection	Scientific value	Objective preferences	Objective preferences	Objective preferences Scientific value

Table 2 documents the varied volume control processes that were utilized over the past year across the noted funding opportunities. There is variability in the operational aspects of the process itself but also who makes the selections and the basis for the selections.

Goals of the Proposed Process

In examining the feedback and outcomes from the preferences-based approach to volume control, there are key goals we sought to accomplish in proposing a different approach as follows:

- Refocus the selection of applications on science rather than strict preferences.

- Align programs with a more consistent volume control process:
 - Applicants can use a unified procedure to apply across programs with minimal variability.
 - Leverage the long-standing learnings of positive selection process (since 2015) to continue making improvements.
- Increase efficiency and the opportunity to learn and implement improvements across programs.

The proposed approach which we term “GWG selection” is a slight modification of the existing positive selection process utilized by the GWG to narrow a pool of applications. The process can be adapted to each of the different funding opportunities, but with some differences related to the expected application volume as shown in Table 3 below.

Table 3. Proposed Use of GWG Selection for Volume Control. Proposed changes from current process are in red.

Selection Process	Positive Selection (existing)	GWG Selection DISC4	GWG Selection PDEV	GWG Selection CLIN2
Submission	Full App	Pre Sub Form	Full App	Full App
Reviewer Scoring	Advance or Not	Select & Rank	Select & Rank	Score & Rank
Expected Reviewer Number	15	15-30	15-20*	15
Assignments	Optional	Required	Required	Required
Number of Apps per Reviewer	Open but must review minimum number	Fixed, must review same as all others	Fixed, must review same as all others	Fixed, must review same as all others

GWG Selection Process Overview

The proposed approach which we term “GWG selection” is a modification of the existing positive selection process. The process can be adapted to each of the different funding opportunities, but with some differences related to the expected application volume as shown in the table below.

The GWG selection process will be applied to all programs requiring volume control (e.g., DISC4, DISC5, PDEV, CLIN2). A target number of applications to be reviewed by the full GWG panel will be established for each funding opportunity and cycle. The target number is based on preserving a high level of rigor in performing the evaluations by the 15 appointed scientific members of the working group along with the 7 patient advocate members (as prescribed in Prop 71 & 14). The number of available awards and expected

* This number assumes two PDEV cycles per year. If ICOC approves one PDEV cycle per year, the expected review number would be 30-40.

success rate may also be considered in determining the number that advances to full review to ensure that the pool is sufficient while allowing for robust time and discussion during the GWG meeting phase.

GWG panels are tailored in their composition to the specific set of applications reviewed to ensure that the expertise is well matched. Recruitment of appropriate reviewers includes identifying specialists that can enhance the expertise of the panel. For CIRM, a complete evaluation may include elements not always present in other funding programs such as elements of population impact and patient access.

The target number and number of submissions (in a given funding cycle) determine the necessary parameters for setting up the GWG selection. If the number of submissions is at or below the target number then no selection is necessary. Otherwise, the number of reviewers, number of reviews per application, number of applications per batch, and total reviews required will be set to optimize the selection and ranking of the application pool.

The table below shows these parameters for different application pool sizes and different targets that approximate what we would expect across the four funding opportunities shown.

	DISC5	DISC4	PDEV	CLIN2
Application Pool	200	100	75	20
Target for Advancement	50	24	30	10
Reviewers (Total number)	20	20	20	20
Applications/Reviewer	30	20	15	5
Reviews per Application	3	4	4	5
Total Reviews Needed	600	400	300	100

Illustrative Example of the Process

To illustrate the process, we provide an example where we follow the fate of an application within a pool of 75 applications (such as PDEV). The goal is to narrow the pool to about 30 applications that advance to GWG panel review.

The illustrated process in brief:

- The pool of 75 applications is split into 20 overlapping batches of 15 applications each.
- Each batch is assigned to one of 20 total scientific reviewers.
- For a sample application:
 - Each application will be contained within the batches of 4 different reviewers (out of the 20 total reviewers).
 - Each of the reviewers will select and rank the best 5 applications in their batch.

- The sample application is selected by 3 out of the 4 reviewers that had the application in their batch.
- Two reviewers ranked it as their favorite (#1 rank) and one ranked it as their second favorite (#2 rank). There is no rank for unselected applications.
- A composite score is calculated for the sample application

How Is a Composite Score Calculated?

Applications are each given a composite score that combines two measurements from the scientific reviewers, selection and rank. The fraction of reviewers that selected the application measures the breadth of interest in the application, whereas the rank given by reviewers measures the intensity of interest by the reviewers. The two measurements are weighted 60% and 40% respectively to prioritize the breadth of interest over the intensity of interest. This, in part, mitigates ranking differences based on differences in quality within batches. Therefore, the formula to calculate the composite score becomes the following:

$$60\% \times \text{Selection} + 40\% \times \text{Rank}$$

For the sample application we can plug in values derived from the 4 reviewers’ selections and rankings. Selections are converted into a binary value of 1 if selected and 0 if not selected. Rankings are converted into values that assigns 5 points to the top rank, 4 points to the second rank, 3 points to the third rank, etc. The two measures are normalized by dividing the total points by the total possible points.

	Selections	Selection Points	Rankings	Ranking Points
Reviewer 1	Yes	1	1	5
Reviewer 2	Yes	1	2	4
Reviewer 3	No	0	-	0
Reviewer 4	Yes	1	1	5

Plugging in the values:

$$\begin{aligned}
 &60\% \times (3 \text{ selections} / 4 \text{ possible selections}) + 40\% \times (14 \text{ rank pts} / 20 \text{ possible rank pts}) \\
 &= 60\% \times (0.75) + 40\% \times (0.70) \\
 &= 0.45 + 0.28 \\
 &= 0.73
 \end{aligned}$$

How Might a Composite Score Affect Outcomes?

The range of composite scores is 0 to 1 with 1 being a perfect score. The purpose of the composite score is to combine two measurements but also to create a rank order of applications. Utilizing a composite of selection and ranking spreads the scores sufficiently to allow for a narrow range to establish a cut-off near the target number of applications. One measurement alone does not provide sufficient granularity.

Where the cut-off falls among the composite scores is dependent on several factors including target number, total pool size, and number of reviewers per application. For the example described here, the cut-off will typically fall between 0.30 and 0.35.

The table below shows how selections and rankings from 4 reviewers and the resulting composite score would affect outcomes.

Scenario	Picks	Rankings	Composite Score	Outcome
All pick, all rank #1	4/4	#1, #1, #1, #1	1.000	Clear Advance
All pick, mixed ranks	4/4	#1, #2, #3, #4	0.880	Clear Advance
3 of 4 pick	3/4	#1, #2, #1	0.730	Advance
2 of 4 pick	2/4	#1, #3	0.460	Advance
1 of 4 picks	1/4	#1	0.250	Filtered
Nobody picks	0/4	—	0.000	Filtered

Comparison of Ranking Versus Scoring in the Selection Process

Per Science Subcommittee request on March 19, we will provide some data comparing the proposed method of selection and ranking versus selection and scoring.

Establishing the Cut-off

- Cut-off will be set at the closest numerical break (i.e., no ties) to the target number of applications, not to exceed 10% more or fewer than target. Defining the range by a percentage allows us to apply this rule across the variable target numbers for each funding opportunity.
- If a clear break does not exist in this range, the range of applications will be randomized to select up to the target number and avoid any bias selection. Several funding agencies are now testing or utilizing randomization as method to select among otherwise equally fundable proposals that cannot all be funded.

	Rank	Composite Score	Outcome
	28	0.3400	Advances
	29	0.3200	Tied - Advances
Target →	30	0.3200	Tied - Advances
	31	0.3200	Tied - Advances
Cut-off →	32	0.3067	Does Not Advance

Applications that advance will be reviewed and scored against the full set of criteria by the GWG.

The Final Step

- The CIRM President, with recommendation from CIRM scientific staff, will examine applications below the cut-off and may advance a limited number of additional applications.
- Advancement would be based on identifying an application that represents a unique opportunity aligned with the goals of the funding opportunity.
- Reviewers may provide brief comments or categorical assessments on the reviewed applications, but feedback to applicants is not guaranteed at this stage of review.

Patient Advocate Role in the Review Process

- CIRM staff is soliciting feedback from Patient Advocate members of the GWG and will continue to work with this group to fully develop the role.
- Given the goal of focusing volume control selection on scientific value, Patient Advocate members' role will be focused on the subsequent full GWG panel discussion (i.e., applications that advance to panel discussion).
- To strengthen the Patient Advocate role at the full GWG panel discussion we are proposing:
 - To define and include a Patient Perspective score

Patient advocate members have a very important role in the review process by providing a perspective that helps the GWG assess whether a proposed therapy has value that is ultimately meaningful to patients. We propose that this score, which is separate from the scientific score, will provide an additional dimension that the Application Review Subcommittee may consider in its programmatic review of PDEV and CLIN2 applications.

- Facilitate discussion between patient advocate members and the GWG chair prior to each GWG review.

Scientific and patient advocate members of the GWG have a good partnership on the GWG, but having additional opportunities to engage ahead of a review meeting can help highlight and strengthen the patient voice to benefit the review.

GWG Selection: Criteria

The Selection Criteria to be used by the GWG (i.e., to select which applications advance to full evaluation) will be aligned with the Guiding Principles for that program and will also incorporate the first element of the full review criteria defined in the Program Announcement for that funding opportunity. Applications that advance will be reviewed and scored against the full set of criteria by the GWG. The Criteria for GWG selection of applications for each program are listed below.[†]

[†] Selection criteria in this memo are not final. Final criteria will be published in the Program Announcements.

Criteria for GWG selection of CLIN2 applications: Scientific Value

- The therapy's potential to provide a meaningful and significant improvement in clinical outcomes compared to therapies currently available or in development.
- Impact of addressing the unmet medical need on patients, caregivers and healthcare system.
- The extent to which the applicant presents a credible, stage appropriate strategy to enable patient access to the proposed therapy for the intended population.
- Feasibility and practicality of the therapy's uptake by patients, caregivers, and healthcare system.

Criteria for GWG selection of PDEV applications: Scientific Value

- The therapy's potential to provide a meaningful and substantial improvement in clinical outcomes for the intended population as compared to therapies currently available or in trials.
- Impact of addressing the unmet medical need on patients, caregivers, and the healthcare system
- The applicant's strategy to improve patient access to the proposed therapy.
- Feasibility and practicality of the therapy's uptake by patients, caregivers, and healthcare system.

Criteria for GWG selection of DISC4 applications: Scientific Value

- Impact of the proposed project in advancing understanding of a human disease, generating data/resources, or where outcomes rapidly advance a therapeutic or biomarker.
- Innovation relative to the current state of research such as applying novel frameworks to study of disease, cutting across silos, employs unique synergy of technologies, or utilizing innovative approaches.

Applying GWG Selection on Full Applications vs. Pre-submissions

Applying GWG Selection on a full application benefits programs where the assessment of readiness elements and availability of supporting project information is critical to the selection. For PDEV and CLIN2, benefits of GWG selection on a full application include:

- Completeness of project information for GWG selection. Survey of GWG reviewers indicates that the majority (95%) use the full application to make final selections.
- Ensures that eligibility can be fully determined: unlikely that an ineligible application takes up a valuable slot.
- Ensures selected projects are at the appropriate stage of readiness with all regulatory, CMC, and product development elements in place (PDEV & CLIN2).
- The time from submission to award is significantly shorter and mitigates project changes and "staleness" over time.

In DISC4, where a new focus area is selected annually and success hinges on forming novel multi-disciplinary teams, GWG selection on a pre-submission allows new teams more time to form and respond to a focus area once it is announced.

2. Guiding Principles in GWG Review

The GWG evaluates selected applications based on review criteria defined in each Program Announcement. These criteria are designed to provide a thorough scientific evaluation grounded in program objectives and Guiding Principles. Full review criteria for DISC4, PDEV, and CLIN2 programs are provided in [Appendix C](#) for reference.

3. Guiding Principles in ARS Decisions

The CIRM team has historically provided recommendations and analysis to support the ARS in making informed funding decisions. The ARS may consider these recommendations along with GWG summaries and public comment in its funding decisions. CIRM team recommendations will be grounded in a standard assessment of programmatic factors that map to Guiding Principles. Specifically, these factors complement the GWG summaries with portfolio and research landscape information and, in the case of CLIN2, may consider comments from Access Specialist reviewers. The following tables describe the assessments that will be performed for each program and how those assessments align with Guiding Principles.

In the case of the PDEV and CLIN2 programs, the following programmatic factors are assessed:

PDEV/CLIN2 Guiding Principle	How the Guiding Principle is Assessed
Transformative Clinical Impact	<ul style="list-style-type: none"> Comparison to active awards & external landscape within the same indication
Patient Access	<ul style="list-style-type: none"> Summary of Access Specialist Reviewer sentiment CIRM knowledge of the modality / route of administration
Disease Representation	<ul style="list-style-type: none"> Disease area representation of active CIRM portfolio

In the case of the DISC4 program, the following programmatic factors are assessed:

DISC4 Guiding Principle	How the Guiding Principle is Assessed
Multidisciplinary research approach	<ul style="list-style-type: none"> N/A – assessment provided in GWG review summary
Collaboration, network synergy, & data leverage	<ul style="list-style-type: none"> Consideration of research approaches and topic area compared to active DISC portfolio & pending awards
Neuro Task Force & other organizational priorities	<ul style="list-style-type: none"> Fit within annual focus area Additional considerations concerning evolving research landscape and funding needs

CIRM team recommendations may incorporate the following additional information:

- Available program budget (oversubscribed versus annual budget remaining)
- GWG score & comments
- Prior awardee performance

- New information available to CIRM after GWG review
 - This may include scientific or administrative information that comes to CIRM's attention through direct communication with applicants or institutions, peer reviewed publications, or public announcements.

CIRM team recommendations will be delivered in a memo to the ARS. The memo will contain:

- A summary of budget utilization
- CIRM team recommendations for each application under consideration
- A summary of key factors (budget utilization, GWG score, or programmatic factors) that drove CIRM team recommendations
- The CIRM team's assessment of programmatic factors for:
 - Any applications which received a Minority Report (35% or more of the GWG scored the application in a fundable range)
 - Any application where the CIRM team recommendation differs from the GWG recommendation
 - Any applications with a GWG score above or tied with the lowest-scoring application for which the CIRM team recommendation differs from the GWG recommendation

Applicants will be informed of the CIRM Team recommendation at the time they receive their GWG review outcomes. A sample ARS memo is provided in [Appendix D](#).

The Application Review Subcommittee (ARS) will make final funding determinations informed by both the GWG's assessment of scientific merit and the CIRM team's structured analysis.

Proposal for DISC4 FY26/27 Funding Area

Strategic Focus as a Catalytic Instrument

DISC4 supports coordinated, multidisciplinary research at a larger scale and level of maturity within the Discovery Program.

Its purpose is not to preserve breadth across the entire discovery landscape, but to enable concentrated investment in defined scientific areas where coordinated effort may accelerate discovery and facilitate transition toward downstream development. Selection of this scientific area is informed by DISC4 Guiding Principles.

In the FY25/26 Program Announcement, DISC4 remained open to all eligible discovery-stage proposals but prioritized neurological diseases (including disorders of the brain, spinal cord, and peripheral nervous system) during the pre-submission and programmatic consideration stages. This cycle-specific prioritization was informed by NTF recommendations and portfolio analysis, while preserving the broader discovery scope of the program.

DISC4 FY26–27 Proposal: Immune–Tissue Interplay in Disease, Homeostasis, and Repair

This thematic focus:

- Applies across a broad spectrum of diseases affecting Californians (fibrosis, autoimmune disease, inflammatory disorders, neurodegeneration, organ failure, oncology, injury),
- Naturally lends itself to multidisciplinary and omics-driven approaches characteristic of DISC4,
- Enables identification of novel targets and biomarkers distinguishing maladaptive versus productive repair,
- Supports development of improved human stem cell and organoid models, and
- Creates strong opportunities for network synergy across funded programs

As with prior cycles, implementation would occur at the pre-submission stage, with topic clarity provided upfront. Pre-submissions will be filtered to final invited applications by the GWG Selection process described above.

PDEV Cycle Recurrence

When the Preclinical Development Program (PDEV) was approved by the ICOC on March 27, 2025, the concept plan had specified two application funding cycles per fiscal year. After careful evaluation of the application cycle frequency for this program as detailed below, the CIRM Team seeks Board approval to revise the PDEV concept plan to specify one application funding cycle per fiscal year.

Two Application Cycles Per Fiscal Year

Some of the key advantages of incorporating two application funding cycles per fiscal year are listed below along with their applicability to the PDEV Program. As the table indicates, due either to the features of the PDEV program or practical implications of the CIRM application lifecycle, most of these advantages don't apply to the PDEV program.

Potential Benefit of Two Cycles per Fiscal Year	Applicability to PDEV Program
Alignment of application cycle availability with project readiness	The PDEV program is designed to allow for application submission at any entry point across the preclinical development lifecycle. In the two cycles to date, applications have ranged from very early projects starting with candidate optimization activities to later-stage projects that have conducted a pre-IND meeting and have started IND-enabling activities.
Applications can be resubmitted in the next application cycle with limited delay	In the two cycles to date, due to partial overlap of submission cycles, it was not possible for an application to immediately resubmit in the next cycle. The length of the application lifecycle from submission through ARS approval does not make it feasible to incorporate two non-overlapping application cycles in the same fiscal year.
Batching of application review, ARS review, and award launch throughout the fiscal year	The first PDEV cycle allocated \$117.6M of the \$160M Fiscal Year Program Budget leaving only \$42.4M for the second PDEV cycle. Given this experience, we expect the first cycle of the fiscal year to have much higher applicant demand than the second cycle.

Practical Implications of One PDEV Cycle Per Fiscal Year

The shift to a single PDEV application funding cycle per fiscal year has the following practical implications:

- All submitted applications compete for the full program budget.
- Unfunded applications may re-submit in the next fiscal year application cycle (approximately 6 months later).
- Higher volume of applications reviewed to account for full program budget.
- Program updates are efficiently implemented in the next fiscal year application cycle.
- Application availability, application due date, review cycles and award contracting timelines are optimized to meet PA requirements and minimize calendar conflicts (i.e. holiday periods).

Requested Action

CIRM requests ICOC approval of the following:

- Amendments to the DISC4, PDEV, and CLIN2 concept plans
- Implementation of the proposed GWG selection process in all programs requiring volume control

- The DISC4 program focus area for the FY 26/27 funding cycle
- A once per year PDEV funding cycle

Exhibits to Memo:

- CLIN2 Concept Clean Copy 26MAR2026
- CLIN2 Concept Tracked Changes 26MAR2026
- PDEV Concept Clean Copy 26MAR2026
- PDEV Concept Tracked Changes 26MAR2026
- DISC4 Concept Clean Copy 26MAR2026
- DISC5 Concept Tracked Changes 26MAR2026

Appendix A. Outcomes of preference scoring from the first cycles of PDEV, CLIN2, and DISC4

Original Intent of Preferences

Preferences were introduced in FY25/26 as a tool for volume control and portfolio shaping, not as a replacement for scientific merit review.

As presented to the Board in January, Preferences were intended to shape portfolio trajectory early in the application lifecycle (i.e. before full GWG review) while maintaining scientific rigor as the central evaluative mechanism.

The design assumption was that strategic steering and review efficiency could be integrated into a single process step. The first cycles provided an opportunity to test that assumption.

Implementation of Preferences in PDEV and CLIN2 Programs

For both PDEV and CLIN2 programs, the preferences were implemented in application volume filtering mechanisms prior to Grants Working Group Review. The implementation of application volume preferences differed between the two programs.

The CLIN2 program retained the prior Qualification mechanism but with the incorporation of preferences as objective scoring criteria.

The PDEV Program incorporated a pilot of a new Pre-submission process that allowed for staff filtering based on preferences and other criteria prior to invitation for submission of full applications. The PDEV Pre-Submission Process incorporated objective scoring of preferences as well as scoring for under-represented disease area and novelty of therapeutic approach to allow for a balanced portfolio of applications for GWG review.

For FY 25/26, the preferences were designed to enrich the portfolio for:

1. Therapeutic technologies that could address known A&A barriers
2. CNS diseases
3. Project acceleration potential (progressions, regulatory milestones, late-phase trials)

Summary of FY 25/26 PDEV and CLIN2 Application Cycle Volume Filtering Outcomes

CLIN2

Across two CLIN2 application cycles, the qualification process resulted in applications that were enriched for in vivo genetic therapy, PSC-derived therapies and CNS diseases compared to the application pool. Of the 13 applications that were forwarded to GWG Review, 12 met in vivo gene therapy and/or CNS disease preference. The single application that did not meet either of these preferences was selected by the GWG via the tie-breaking process.

PDEV

The PDEV Pre-Submission process deployed a weighted scoring process across four criteria: Prop 14 preferences (PSC-derived, in vivo GT, CNS), Other Preferences, Under-Represented Disease Area, Novelty of Approach. This rubric was intended to allow for a broad range of projects to be invited for submission, including novel therapeutic approaches that did not specifically meet preference scoring. The rubric was slightly modified between Cycle 1 and Cycle 2: the weight of the under-represented disease area preference was reduced from 2 to 1, and the comparator set for under-represented disease area and novelty scoring was expanded from active CLIN2 awards to active TRAN1/CLIN1/CLIN2 awards. In both cycles, an objective tie-breaker was used to achieve the target application volume in applications with an identical score. For cycle 1, the tie-breaker was used on pre-submissions scoring 6 points and pre-submissions that met the CNS and progressions preferences were selected. For cycle 2, the tie-breaker was used on pre-submissions scoring 5 points and pre-submissions with the highest disease prevalence were selected.

Cycle 1 (168 submitted, 33 invited): The pre-submission process resulted in enrichment for in vivo genetic therapies, PSC-derived therapies, non-viral nucleic acid delivery, under-represented disease area and portfolio progression preferences compared to the full pre-submission pool. The process resulted in under-representation of projects that utilized autologous cell therapy modalities or projects that targeted the oncology disease areas compared to the full pre-submission pool. It resulted in no representation of projects that targeted the hematology disease area. Hematology and oncology are two of the highest represented disease areas in the CIRM active awards portfolio. With respect to the influence of novelty scoring, only one invited pre-submission did not meet one of the Prop 14 preferences. The novelty scoring selected for novel approaches within the pool of pre-submissions that scored for the Prop 14 preferences.

Cycle 2 (126 submitted, 23 invited): The pre-submission process resulted in enrichment for PSC-derived therapies, non-viral nucleic acid delivery and portfolio progressions. With respect to the influence of novelty score, no pre-submissions were invited for application that did not meet one of the Prop 14 preferences. The novelty scoring did select for novel approaches within the pool of pre-submissions that scored for the Prop 14 preferences. With respect to disease area representation, the metabolic disease area was over-represented and oncology disease area was under-represented in the invited pre-submissions compared to the pre-submission pool.

CIRM Team Observations on the Preferences and Volume Filtering Process for PDEV & CLIN2

The preferences and volume filtering processes as currently designed, while effective in rapidly filtering the volume, have the following limitations:

- The specificity of preferences, while advantageous for transparency and objectivity, result in a subset of preferences having a disproportionate effect on the filtering outcomes.
- The preferences and preference-based volume filtering process, as currently designed, will require continuous monitoring and adjustment by CIRM and the ICOC to align with strategic portfolio goals.

Implementation of Preferences in DISC4: Strategic Focus as a Catalytic Instrument

Where PDEV and CLIN2 function as broad translational programs requiring portfolio-level steering, DISC4 was approved as part of a complementary discovery-stage award structure designed to support coordinated, multidisciplinary research at a larger scale and level of maturity within the Discovery Program. Its purpose is not to preserve breadth across the entire discovery landscape, but to enable concentrated investment in defined scientific areas where coordinated effort may accelerate discovery and facilitate transition toward downstream development.

Thus, in DISC4, “Preference” is not a tool to shape portfolio balance but rather a strategic instrument to implement a scientific focus. As conceived in the DISC4 concept, the board will approve an area of focus on an annual basis. In March 2025, CIRM’s board selected “Neurological Diseases (including conditions and disorders of the brain, spinal cord, and peripheral nervous system) as the preference topic for the FY 25-26 Cycle.

The DISC4 concept also piloted use of a Pre-submission process to help enrich for proposals that would be best suited to benefit from the DISC4 grant mechanism, where the nature and scale of investment is most likely to yield transformative impact. Pre-submissions were short project summaries that were evaluated by the CIRM team using an objective rubric to determine which would be invited to submit a full application (shown below). Thus, similar to the processes developed for PDEV and CLIN2, the use of Preferences served the dual purpose of prioritization and volume control.

Within CIRM’s Discovery Program:

- DISC5 supports comprehensive discovery research across a diverse range of diseases and bottlenecks, funding exploratory and innovative foundational research that employs human stem cells and/or genetic research as a central approach. It is not topic-restricted.
- DISC4 was structured as a focused discovery opportunity, operating at a different scale and supporting multidisciplinary teams aligned around defined scientific themes, affording the potential to leverage data and resources across a network to maximize scientific impact.

DISC4's focused structure traces back to the ReMIND Program, developed in response to Proposition 14's CNS mandate and refined in partnership with the Neuroscience and Medicine Task Force (NTF). While ReMIND-L strategically focused on neuropsychiatric disorders based on scientific opportunity and portfolio considerations at that time, the broader ReMIND vision was to catalyze multidisciplinary networks addressing fundamental gaps across CNS diseases. That experience demonstrated the value of defined thematic calls in driving convergence and shared infrastructure. The current DISC4 iteration builds on that structural model through a rotating focus approach that preserves NTF-driven scientific prioritization within the CNS mandate while maintaining DISC4 as an open, all-comers discovery platform. Thematic emphasis alternates by cycle and is informed by NTF recommendations, portfolio analysis, and annual Board consideration. Its focused elements therefore reflect intentional program design and Board-level strategy.

In the FY25/26 Program Announcement, DISC4 remained open to all eligible discovery-stage proposals but prioritized neurological diseases (including disorders of the brain, spinal cord, and peripheral nervous system) during the pre-submission and programmatic consideration stages. This cycle-specific prioritization was informed by NTF recommendations and portfolio analysis, while preserving the broader discovery scope of the program.

Summary of FY 25/26 DISC4 Application Cycle Volume Filtering Outcomes

The results of the 2025-2026 cycle indicate that prospective applicants understood that DISC4 was focused on a defined scientific topic and that this area of focus would be implemented through the use of a rubric. Of the 138 pre-submissions received, 86% were focused on neurological conditions encompassing a broad array of topics including neurodegeneration, neurodevelopment, and neuro-oncology. The remainder focused on non-neurological systems. Topics and score distribution across all pre-submissions can be viewed in Table 4B.

Due to the anticipated size and complexity of DISC4 applications, CIRM targeted 20 to 24 projects for Grants Working Group Review. Following the use of the rubric, the top scoring teams were invited to submit full applications. All 24 addressed the neurological focus area and like the starting pool, reflected a broad diversity of topics. However, given the high number of pre-submissions, the practical effect was that projects outside the defined focus area (even those with potential for high impact) had limited opportunity to advance.

This was not the result of hidden gating mechanics, but rather the predictable outcome of a tightly scoped thematic call combined with high demand.

This highlights a different strategic insight than that observed in PDEV and CLIN2. For DISC4, the central question is not how to refine gating mechanics, but how to calibrate scope and thematic breadth when the Board wishes to signal openness to a wider range of high impact science.

CIRM Team Observations on the DISC4 Implementation Process

- A clearly defined focus area attracted a highly targeted pool of applications
- Scientific quality remained strong under the focused call
- Defined themes promote scientific leverage within and across projects
- Defined themes allowed a review panel with more specialized and relevant expertise to be assembled
- When demand is high, a thematic focus functions as a practical filter

The strategic question for DISC4 is therefore different from that of PDEV and CLIN2 Preferences. It is not whether upstream gating is appropriate; it is how focus should be defined, calibrated, and iterated over time to maximize impact.

Table 1. FY25/26 Preferences & Volume Control by Program

	PDEV	CLIN2	DISC4
Preferences	<ul style="list-style-type: none"> • Pluripotent stem cell-derived therapies • In vivo genetic therapies • Therapies using non-viral nucleic acid delivery • Projects addressing diseases of the brain and CNS • Projects progressing from DISC2 & TRAN1 Awards • Projects in which a pre-IND or INTERACT meeting has been conducted 	<ul style="list-style-type: none"> • Pluripotent stem cell-derived therapies • In vivo genetic therapies • Therapies using non-viral nucleic acid delivery • Projects addressing diseases of the brain and CNS • Applications from California organizations • Projects progressing from CIRM-funded IND-enabling or earlier phase clinical trial awards • Projects with Fast Track, RMAT or Breakthrough designations • Projects proposing pivotal clinical trials (as agreed-to by the FDA) 	<ul style="list-style-type: none"> • FY25-26 Focus Area: Neurological Diseases • Relevance to human disease biology • Cross-disciplinary and systems biology • Stem cell or genetic research innovations
Volume Control Method	<ul style="list-style-type: none"> • Point-based preference scoring of pre-submissions 	<ul style="list-style-type: none"> • Point-based preference scoring of applications • GWG tie-breaking 	<ul style="list-style-type: none"> • Point-based preference scoring of pre-submissions

CNS: Central Nervous System; IND: Investigational New Drug Application; INTERACT: Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products; RMAT: Regenerative Medicine Advanced Therapy

Table 2A. PDEV FY25/26 Preference Scoring Rubric

Preference	Points
At least one of the following: PSC derived therapies In vivo genetic therapies Diseases of the CNS	
Non viral nucleic acid delivery	1
Pre IND or INTERACT meeting conducted	1
Progression from DISC2 or TRAN1	1
Targeting disease area under represented in CIRM active awards portfolio	1
Novelty of therapeutic approach compared to CIRM active awards portfolio	2

PSC: Pluripotent Stem Cell; CNS: Central Nervous System; IND: Investigational New Drug Application;
 INTERACT: Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products

Table 2B. PDEV Cycle 1 Preference Scoring Results (1 of 4)

Modality	Disease Area	Total Score	Invited*	Funded
Genetic therapy (cell free)	Muscle Disorders	3 1 1 2 2	✓	✗
Autologous cell therapy	Other rinary disorders	3 1 1 2 2	✓	✓
Genetic therapy (cell free)	Muscle Disorders	3 1 2 2	✓	✗
Genetic therapy (cell free)	Muscle Disorders	3 1 2 2	✓	✓
Allogeneic cell therapy	Muscle Disorders	3 1 2 2	✓	✗
Genetic therapy (cell free)	Respiratory Disorders	3 1 2 2	✓	✗
Genetic therapy (cell free)	Cardiovascular Disorders	3 1 2 2	✓	✗
Genetic therapy (cell free)	Respiratory Disorders	3 1 2 2	✓	✓
Allogeneic gene modified cell therapy	Cardiovascular Disorders	3 1 2 2	✗	✗
Autologous gene modified cell therapy	Neurologic Disorders	3 1 1 1 2	✓	✓
Genetic therapy (cell free)	Skin Disorders	3 1 2 2	✗	✗
Allogeneic cell therapy	Muscle Disorders	3 1 2 2	✓	✗
Genetic therapy (cell free)	Cardiovascular Disorders	3 1 1 2 1	✓	✓
Genetic therapy (cell free)	Cardiovascular Disorders	3 1 1 2 1	✓	✓
Genetic therapy (cell free)	Cardiovascular Disorders	3 1 2 2	✓	✓
Genetic therapy (cell free)	Bone & Cartilage Disorders	3 1 2 2	✓	✗
Allogeneic cell therapy	Bone & Cartilage Disorders	3 1 2 2	✓	✓
Allogeneic cell therapy	Cardiovascular Disorders	3 1 2 2	✓	✗
Autologous gene modified cell therapy	Neurologic Disorders	3 1 1 2	✓	✗
Genetic therapy (cell free)	Metabolic Disorders	3 1 1 2	✓	✗
Autologous gene modified cell therapy	Respiratory Disorders	1 1 1 2 2	✓	✗
Genetic therapy (cell free)	Metabolic Disorders	3 1 1 2	✓	✗
Genetic therapy (cell free)	Metabolic Disorders	3 1 1 2	✓	✗
Allogeneic cell therapy	Neurologic Disorders	3 1 1 2	✓	✓
Genetic therapy (cell free)	Muscle Disorders	3 2 2	✓	✗
Genetic therapy (cell free)	Metabolic Disorders	3 1 1 2	✓	✓
Genetic therapy (cell free)	idney Disease	3 1 1 2 2	✓	✗
Genetic therapy (cell free)	Cardiovascular Disorders	3 1 2 1	✓	✗
Allogeneic gene modified cell therapy	Metabolic Disorders	3 1 1 2	✓	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 2	✓	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 1 1	✓	✗
Small molecule	Brain Cancers	3 1 1 1	✓	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 1 1	✓	✓
Allogeneic gene modified cell therapy	Neurologic Disorders	3 1 1 1	✗	✗
Allogeneic cell therapy	Eye Vision Disorders, Neurological	3 1 1 1	✓	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 2	✗	✗
Small molecule	Neurologic Disorders	3 1 2	✗	✗
Autologous gene modified cell therapy	Neurologic Disorders	3 1 2	✗	✗
Autologous gene modified cell therapy	Neurologic Disorders	3 1 2	✗	✗
Autologous gene modified cell therapy	Neurologic Disorders	3 1 2	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 2	✗	✗
Allogeneic gene modified cell therapy	Neurologic Disorders	3 1 2	✗	✗



■ PSC ■ Neuro ■ In vivo ■ Non Viral Nucleic Acid ■ Meeting Conducted ■ Progression ■ nder Represented Disease Area ■ Novelty

Table 2B. PDEV Cycle 1 Preference Scoring Results (2 of 4)

Modality	Disease Area	Total Score	Invited*	Funded
Genetic therapy (cell free)	Neurologic Disorders	3 1 2	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 1 2	×	×
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	3 1 2	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 1 2	×	×
Biologic, excluding gene therapy	Cardiovascular Disorders	1 1 2 2	×	×
Biologic, excluding gene therapy	Cardiovascular Disorders	1 1 2 2	×	×
Biologic, excluding gene therapy	Metabolic Disorders	3 1 1 1	×	×
Autologous cell therapy	ematology Disorders	3 1 2	×	×
Allogeneic cell therapy	Cardiovascular Disorders	3 1 2	×	×
Genetic therapy (cell free)	Solid Tumors	3 1 2	×	×
Allogeneic cell therapy	Cardiovascular Disorders	3 2 1	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 1 2	✓	✓
Genetic therapy (cell free)	Solid Tumors	3 1 1	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 1 1	×	×
Genetic therapy (cell free)	Cancers, Multiple Types Sites	3 1 1	×	×
Genetic therapy (cell free)	ematologic Malignancies	3 1 1	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 2	×	×
Small molecule	Neurologic Disorders	3 2	×	×
Allogeneic gene modified cell therapy	Metabolic Disorders	3 1 1	×	×
Genetic therapy (cell free)	Bone & Cartilage Disorders	3 2	×	×
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	3 1 1	×	×
Genetic therapy (cell free)	Cardiovascular Disorders	3 2	×	×
Biologic, excluding gene therapy	Brain Cancers	3 1 1	×	×
Autologous cell therapy	Neurologic Disorders	3 2	×	×
Autologous cell therapy	Neurologic Disorders	3 1 1	×	×
Genetic therapy (cell free)	Eye Vision Disorders, Non neurological	3 1 1	×	×
Allogeneic gene modified cell therapy	Bone & Cartilage Disorders	1 2 2	×	×
Allogeneic cell therapy	Neurologic Disorders	3 1 1	×	×
Allogeneic cell therapy	Cardiovascular Disorders	3 2	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 2	×	×
Genetic therapy (cell free)	ematologic Malignancies	3 2	×	×
Genetic therapy (cell free)	Cardiovascular Disorders	3 2	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 2	×	×
Genetic therapy (cell free)	Cardiovascular Disorders	3 2	×	×
Genetic therapy (cell free)	Brain Cancers	3 1 1	×	×
Genetic therapy (cell free)	Cardiovascular Disorders	3 2	×	×
Small molecule	Brain Cancers	3 1 1	×	×
Genetic therapy (cell free)	Brain Cancers	3 1 1	×	×
Genetic therapy (cell free)	Brain Cancers	3 1 1	×	×
Allogeneic cell therapy	Neurologic Disorders	3 1 1	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	×	×
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	×	×

■ PSC ■ Neuro ■ In vivo ■ Non Viral Nucleic Acid ■ Meeting Conducted ■ Progression ■ nder Represented Disease Area ■ Novelty

Table 2B. PDEV Cycle 1 Preference Scoring Results (3 of 4)

Modality	Disease Area	Total Score	Invited*	Funded
Genetic therapy (cell free)	Infectious Diseases	 4	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 4	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 4	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 4	✗	✗
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	 4	✗	✗
Small molecule	Neurologic Disorders	 4	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 4	✗	✗
Small molecule	Neurologic Disorders	 3	✗	✗
Allogeneic cell therapy	Eye Vision Disorders, Neurological	 3	✗	✗
Small molecule	Brain Cancers	 3	✗	✗
Autologous gene modified cell therapy	ematology Disorders	 3	✗	✗
Allogeneic cell therapy	Bone & Cartilage Disorders	 3	✗	✗
Autologous gene modified cell therapy	Brain Cancers	 3	✗	✗
Allogeneic cell therapy	Other liver failure	 3	✗	✗
Biologic, excluding gene therapy	Neurologic Disorders	 3	✗	✗
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	 3	✗	✗
Allogeneic gene modified cell therapy	Skin Disorders	 3	✗	✗
Allogeneic cell therapy	Neurologic Disorders	 3	✗	✗
Allogeneic gene modified cell therapy	Other, Gastrointestinal	 3	✗	✗
Autologous gene modified cell therapy	Neurologic Disorders	 3	✗	✗
Small molecule	Brain Cancers	 3	✗	✗
Allogeneic cell therapy	Neurologic Disorders	 3	✗	✗
Genetic therapy (cell free)	Cancers, Multiple Types Sites	 3	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 3	✗	✗
Genetic therapy (cell free)	Solid Tumors	 3	✗	✗
Autologous gene modified cell therapy	Neurologic Disorders	 3	✗	✗
Genetic therapy (cell free)	ematologic Malignancies	 3	✗	✗
Autologous cell therapy	Brain Cancers	 3	✗	✗
Allogeneic cell therapy	Eye Vision Disorders, Non neurological	 3	✗	✗
Small molecule	Neurologic Disorders	 3	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 3	✗	✗
Genetic therapy (cell free)	ematologic Malignancies	 3	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 3	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 3	✗	✗
Allogeneic gene modified cell therapy	Cardiovascular Disorders	 3	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 3	✗	✗
Allogeneic gene modified cell therapy	Brain Cancers	 3	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 3	✗	✗
Autologous gene modified cell therapy	Brain Cancers	 3	✗	✗
Genetic therapy (cell free)	Neurologic Disorders	 3	✗	✗
Allogeneic gene modified cell therapy	ematologic Malignancies	 2	✗	✗
Allogeneic cell therapy	Other, genitourinary	 2	✗	✗

■ PSC ■ Neuro ■ In vivo ■ Non Viral Nucleic Acid ■ Meeting Conducted ■ Progression ■ nder Represented Disease Area ■ Novelty

Table 2B. PDEV Cycle 1 Preference Scoring Results (4 of 4)

Modality	Disease Area	Total Score	Invited*	Funded
Allogeneic gene modified cell therapy	Bone & Cartilage Disorders	 2	×	×
Allogeneic cell therapy	Other Liver	 2	×	×
Small molecule	Cardiovascular Disorders	 2	×	×
Autologous cell therapy	idney Disease	 2	×	×
Biologic, excluding gene therapy	Cardiovascular Disorders	 2	×	×
Allogeneic cell therapy	Metabolic Disorders	 2	×	×
Autologous gene modified cell therapy	Solid Tumors	 2	×	×
Small molecule	Respiratory Disorders	 2	×	×
Small molecule	Infectious Diseases	 1	×	×
Allogeneic gene modified cell therapy	Solid Tumors	 1	×	×
Autologous gene modified cell therapy	ematologic Malignancies	 1	×	×
Allogeneic gene modified cell therapy	Solid Tumors	 1	×	×
Autologous gene modified cell therapy	Cancers, Multiple Types Sites	 1	×	×
Autologous gene modified cell therapy	Cancers, Multiple Types Sites	 1	×	×
Biologic, excluding gene therapy	ematology Disorders	 1	×	×
Autologous gene modified cell therapy	Metabolic Disorders	 1	×	×
Autologous gene modified cell therapy	Solid Tumors	 1	×	×
Autologous cell therapy	Solid Tumors	 1	×	×
Autologous gene modified cell therapy	Solid Tumors	 1	×	×
Small molecule	ematologic Malignancies	 1	×	×
Allogeneic gene modified cell therapy	ematology Disorders		×	×
Autologous gene modified cell therapy	Solid Tumors		×	×
Autologous gene modified cell therapy	ematologic Malignancies		×	×
Allogeneic gene modified cell therapy	Solid Tumors		×	×
Allogeneic cell therapy	ematologic Malignancies		×	×
Biologic, excluding gene therapy	Solid Tumors		×	×
Autologous cell therapy	Cancers, Multiple Types Sites		×	×
Allogeneic cell therapy	Eye Vision Disorders, Non neurological		×	×
Autologous gene modified cell therapy	Cancers, Multiple Types Sites		×	×
Allogeneic cell therapy	Cancers, Multiple Types Sites		×	×
Autologous gene modified cell therapy	Solid Tumors		×	×
Biologic, excluding gene therapy	Solid Tumors		×	×
Autologous cell therapy	Solid Tumors		×	×
Allogeneic gene modified cell therapy	Solid Tumors		×	×
Biologic, excluding gene therapy	ematologic Malignancies		×	×
Autologous gene modified cell therapy	ematology Disorders		×	×
Autologous cell therapy	Cancers, Multiple Types Sites		×	×
Allogeneic cell therapy	ematologic Malignancies		×	×
Allogeneic cell therapy	Solid Tumors		×	×
Small molecule	ematologic Malignancies		×	×
Allogeneic gene modified cell therapy	ematologic Malignancies		×	×
Autologous cell therapy	ematologic Malignancies		×	×

 PSC
  Neuro
  In vivo
  Non Viral Nucleic Acid
  Meeting Conducted
  Progression
  nder Represented Disease Area
  Novelty

Table 2C. PDEV Cycle 2 Preference Scoring Results (1 of 3)

Modality	Disease Area	Total Score	Invited*
Genetic therapy (cell free)	Metabolic Disorders		✓
Genetic therapy (cell free)	Bone & Cartilage Disorders		✓
Genetic therapy (cell free)	Other idney Disease		✓
Allogeneic gene modified cell therapy	Metabolic Disorders		✓
Allogeneic gene modified cell therapy	Other Liver Disorders		✓
Allogeneic gene modified cell therapy	Other Liver disorder		✓
Genetic therapy (cell free)	Metabolic Disorders		✓
Allogeneic cell therapy	Other Liver Disorders		✗
Genetic therapy (cell free)	Muscle Disorders		✓
Genetic therapy (cell free)	Neurologic Disorders		✓
Allogeneic cell therapy	Cardiovascular Disorders		✓
Autologous gene modified cell therapy	Neurologic Disorders		✓
Small molecule	Eye Vision Disorders, Neurological		✓
Allogeneic cell therapy	ematology Disorders		✓
Genetic therapy (cell free)	Cancers, Multiple Types Sites		✓
Allogeneic cell therapy	Cardiovascular Disorders		✓
Allogeneic cell therapy	Neurologic Disorders		✓
Genetic therapy (cell free)	Brain Cancers		✓
Genetic therapy (cell free)	Bone & Cartilage Disorders		✗
Genetic therapy (cell free)	Brain Cancers		✓
Genetic therapy (cell free)	e matologic Malignancies		✓
Allogeneic gene modified cell therapy	Neurologic Disorders		✓
Allogeneic cell therapy	Metabolic Disorders		✓
Genetic therapy (cell free)	Cardiovascular Disorders		✗
Allogeneic gene modified cell therapy	Cancers, Multiple Types Sites		✗
Small molecule	Brain Cancers		✗
Genetic therapy (cell free)	Brain Cancers		✗
Genetic therapy (cell free)	Eye Vision Disorders, Neurological		✗
Genetic therapy (cell free)	Eye Vision Disorders, Neurological		✗
Genetic therapy (cell free)	Neurologic Disorders		✗
Allogeneic cell therapy	Eye Vision Disorders, Neurological		✗
Genetic therapy (cell free)	Neurologic Disorders		✗
Genetic therapy (cell free)	Solid Tumors		✗
Genetic therapy (cell free)	Neurologic Disorders		✗
Genetic therapy (cell free)	Neurologic Disorders		✗
Allogeneic cell therapy	Neurologic Disorders		✗
Genetic therapy (cell free)	Metabolic Disorders		✗
Biologic, excluding gene therapy	Brain Cancers		✗
Allogeneic cell therapy	Neurologic Disorders		✓
Genetic therapy (cell free)	Neurologic Disorders		✗
Genetic therapy (cell free)	Infectious Diseases		✗
Genetic therapy (cell free)	Cancers, Multiple Types Sites		✗

■ PSC
 ■ Neuro
 ■ In vivo
 ■ Non Viral Nucleic Acid
 ■ Meeting Conducted
 ■ Progression
 ■ Under Represented Disease Area
 ■ Novelty

Table 2C. PDEV Cycle 2 Preference Scoring Results (2 of 3)

Modality	Disease Area	Total Score	Invited*
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	3 1 1	✗
Allogeneic cell therapy	Neurologic Disorders	3 1 1	✗
Autologous cell therapy	Neurologic Disorders	3 1 1	✗
Allogeneic cell therapy	Metabolic Disorders	3 1 1	✓
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	3 1 1	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 1	✗
Genetic therapy (cell free)	Bone & Cartilage Disorders	3 1 1	✗
Allogeneic cell therapy	Cardiovascular Disorders	3 1 1	✗
Genetic therapy (cell free)	Cardiovascular Disorders	3 1 1	✗
Small molecule	Neurologic Disorders	3 1 1	✗
Small molecule	Eye Vision Disorders, Neurological	3 1 1	✗
Allogeneic cell therapy	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	✗
Autologous gene modified cell therapy	Brain Cancers	3 1 4	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	✗
Autologous gene modified cell therapy	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	3 1 4	✗
Allogeneic cell therapy	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Cancers, Multiple Types Sites	3 1 4	✗
Genetic therapy (cell free)	Muscle Disorders	3 1 4	✗
Allogeneic cell therapy	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	3 1 4	✗
Allogeneic cell therapy	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Eye Vision Disorders, Neurological	3 1 4	✗
Small molecule	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Neurologic Disorders	3 1 4	✗
Genetic therapy (cell free)	Metabolic Disorders	3 1 4	✗
Genetic therapy (cell free)	Brain Cancers	3 1 4	✗
Genetic therapy (cell free)	e matologic Malignancies	3	✗
Genetic therapy (cell free)	Neurologic Disorders	3	✗
Allogeneic gene modified cell therapy	Neurologic Disorders	3	✗
Autologous gene modified cell therapy	Infectious Diseases	1 1 1	✗
Small molecule	Neurologic Disorders	3	✗
Genetic therapy (cell free)	Neurologic Disorders	3	✗
Genetic therapy (cell free)	Neurologic Disorders	3	✗
Autologous cell therapy	Neurologic Disorders	3	✗
Biologic, excluding gene therapy	Neurologic Disorders	3	✗
Biologic, excluding gene therapy	Cardiovascular Disorders	1 1 1	✗
Genetic therapy (cell free)	Solid Tumors	3	✗

■ PSC ■ Neuro ■ In vivo ■ Non Viral Nucleic Acid ■ Meeting Conducted ■ Progression ■ nder Represented Disease Area ■ Novelty

Table 2C. PDEV Cycle 2 Preference Scoring Results (3 of 3)

Modality	Disease Area	Total Score	Invited*
Autologous cell therapy	Brain Cancers	3	✗
Genetic therapy (cell free)	Neurologic Disorders	3	✗
Allogeneic cell therapy	Neurologic Disorders	3	✗
Small molecule	Neurologic Disorders	3	✗
Autologous gene modified cell therapy	Brain Cancers	3	✗
Genetic therapy (cell free)	Solid Tumors	3	✗
Genetic therapy (cell free)	Solid Tumors	3	✗
Genetic therapy (cell free)	Neurologic Disorders	3	✗
Allogeneic gene modified cell therapy	Solid Tumors	3	✗
Allogeneic gene modified cell therapy	Solid Tumors	2	✗
Allogeneic cell therapy	Respiratory Disorders	2	✗
Allogeneic gene modified cell therapy	Solid Tumors	2	✗
Allogeneic gene modified cell therapy	Other Type 1 Diabetes and Transplantation	2	✗
Autologous gene modified cell therapy	Solid Tumors	2	✗
Allogeneic cell therapy	Metabolic Disorders	2	✗
Autologous gene modified cell therapy	Other Immune System disorder	2	✗
Allogeneic gene modified cell therapy	Other, gastrointestinal	2	✗
Autologous gene modified cell therapy	Cancers, Multiple Types Sites	2	✗
Small molecule	Other Dupuytren's & related	1	✗
Small molecule	Immune fibrotic diseases	1	✗
Small molecule	ematologic Malignancies	1	✗
Allogeneic cell therapy	Solid Tumors	1	✗
Small molecule	ematologic Malignancies	1	✗
Autologous gene modified cell therapy	ematology Disorders	1	✗
Allogeneic gene modified cell therapy	ematologic Malignancies	1	✗
Biologic, excluding gene therapy	Cardiovascular Disorders	1	✗
Autologous gene modified cell therapy	Solid Tumors	1	✗
Autologous cell therapy	Solid Tumors	1	✗
Small molecule	Respiratory Disorders	1	✗
Small molecule	Bone & Cartilage Disorders	1	✗
Autologous gene modified cell therapy	Solid Tumors	1	✗
Biologic, excluding gene therapy	ematology Disorders	1	✗
Allogeneic cell therapy	Other Gastrointestinal disorders	1	✗
Small molecule	Muscle Disorders	1	✗
Allogeneic gene modified cell therapy	Solid Tumors	0	✗
Allogeneic gene modified cell therapy	Solid Tumors	0	✗
Autologous cell therapy	Solid Tumors	0	✗
Autologous cell therapy	ematology Disorders	0	✗
Autologous cell therapy	Cancers, Multiple Types Sites	0	✗
Autologous gene modified cell therapy	ematologic Malignancies	0	✗
Allogeneic cell therapy	Solid Tumors	0	✗
Biologic, excluding gene therapy	ematology Disorders	0	✗
Allogeneic gene modified cell therapy	Solid Tumors	0	✗

■ PSC
 ■ Neuro
 ■ In vivo
 ■ Non Viral Nucleic Acid
 ■ Meeting Conducted
 ■ Progression
 ■ Under Represented Disease Area
 ■ Novelty

Table 3A. CLIN2 FY25/26 Qualification Rubric

Preference	Points
PSC derived therapies	1
Diseases of the CNS	1
In vivo genetic therapy	1
Non viral genetic therapy	1
Accelerated regulatory designation (RMAT, Breakthrough, Fast Track)	1
Progression from earlier stage CIRM award	1
California Organization	1
Pivotal trial	2

PSC: Pluripotent Stem Cell; CNS: Central Nervous System; RMAT: Regenerative Medicine Advanced Therapy

Table 3B. CLIN2 Cycle 1 Qualification Results

Description	Total Score	GWG Tie Break	Full Review	Funded
Allogeneic oligodendrocyte progenitor cells for spinal cord injury	4	N A	✓	✗
Allogeneic neural stem cells for Huntington's disease	4	N A	✓	✓
AAV delivered gene regulation therapy for Dravet Syndrome	4	N A	✓	✓
AAV based gene therapy for CMT4	4	N A	✓	✓
Allogeneic dopamine producing neurons for Parkinson's disease	4	N A	✓	✓
Allogeneic retinal progenitor cells for retinitis pigmentosa	3	1 2 .	✓	✗
AAV gene therapy for CLN3 disease	3	122.	✗	✗
Neutrophil therapy for Alzheimer's disease	3	112.	✗	✗
Allogeneic CAR T for solid tumors	3	1 4	✗	✗
AAV delivered epigenetic therapy for facioscapulohumeral muscular dystrophy	3	1 2 .	✗	✗
Allogeneic breast cancer cell based immunotherapy for breast cancer	3		✗	✗
Small molecule for venous leg ulcers	2	N A	✗	✗
Small molecule for AML myelofibrosis	2	N A	✗	✗
AAV delivered genetic therapy for neuropathy	2	N A	✗	✗
Antibody for myocardial infarction	2	N A	✗	✗
Autologous CAR T for multiple myeloma	2	N A	✗	✗
Autologous CAR T for lymphoma	3	N A	✗	✗
Autologous CAR T for B cell cancers	2	N A	✗	✗
Autologous cancer vaccine for AML	2	N A	✗	✗
Antibody based biologic for solid tumors & multiple myeloma	2	N A	✗	✗
Allogeneic MSC cancer vaccine	2	N A	✗	✗
Allogeneic CS T for Crohn disease	1	N A	✗	✗
Extracellular vesicles for acute respiratory distress syndrome		N A	✗	✗

■ PSC derived
 ■ In vivo genetic therapy
 ■ Non viral
 ■ CNS
 Progression
 ■ CA organization
 ■ FDA designation
 ■ Pivotal trial

Table 3C. CLIN2 Cycle 2 Qualification Results

Description	Total Score	GWG Tie Break	Full Review
Genetic therapy for Pitt o pkins Syndrome	4	N A	✓
AAV based optogenetic gene therapy for Stargardt disease	4	N A	✓
Autologous B cells for rare lysosomal storage disorder	4	N A	✓
Autologous iPSC derived cell therapy for blinding eye diseases (geographic atrophy, Stargardt, etc.)	4	N A	✓
Genetic therapy for rare metabolic disorder	4	1 2 .	✓
Epigenetic therapy for FS D	4	1 .	✓
Autologous cancer vaccine for AML	4	1	✗
Autologous CAR T for brain & B cell cancers	4	12 .	✓
Autologous MSC cancer vaccine	4		✗
AAV based gene therapy for dilated cardiomyopathy	2	N A	✗
Allogeneic CAR T for lymphoma	2	N A	✗
Allogeneic MSC for pediatric dilated cardiomyopathy	2	N A	✗
Autologous gene modified S Cs for SCD	2	N A	✗
Small molecule for venous leg ulcers	2	1	✗
Autologous adipose derived stem cells for Al h eimer s disease	2	N A	✗
Autologous CAR T for multiple myeloma	2	N A	✗
Antibody for myocardial infarction	2	N A	✗
Allogeneic CAR Treg for multiple sclerosis	2	N A	✗
Small molecule for myelofibrosis & AML	1	N A	✗
Allogeneic CS T for Crohn s disease	1	N A	✗
Allogeneic breast cancer cell based immunotherapy for breast cancer		N A	✗

■ PSC derived
 ■ In vivo genetic therapy
 ■ Non viral
 ■ CNS
 ■ Progression
 ■ CA organi a tion
 ■ FDA designation
 ■ Pivotal trial

Table 4A. DISC4 Preference Scoring Rubric

Criteria	Description (listed in program announcement)	Points
Preference Topic: Neuro	Does the project align with the cycle specific preference topic	
Relevance to human disease biology	Does the project hold strong relevance for understanding or addressing human diseases	
Cross disciplinary and systems biology	Does the project integrate cross disciplinary approaches	
Stem cell or genetic research innovations	Does the project incorporate innovative approaches particularly in stem cell or genetic research	4

Table 4B. DISC4 Cycle 1 Preference Scoring Results (1 of 3)

Disease Areas	Total Score				Invited*	
Neurologic Disorders	9.00	5.50	4.50	4.00	21	✓
Brain Cancers	8.00	5.00	4.50	4.00	21	✓
Brain Cancers	9.00	5.00	3.50	3.50	21	✓
Neurologic Disorders	9.00	4.67	4.67	2.67	21	✓
Brain Cancers	7.50	4.50	4.50	4.00	21	✓
Neurologic Disorders	7.00	5.50	5.00	2.00	1	✓
Neurologic Disorders	7.00	4.50	4.00	4.00	1	✓
Neurologic Disorders	9.00	3.50	3.00	4.00	1	✓
Eye Vision Disorders, Non neurological	7.50	5.50	3.00	3.00	1	✓
Neurologic Disorders	7.00	4.50	3.50	4.00	1	✓
Cardiovascular Disorders	8.00	3.50	4.50	3.00	1	✓
Neurologic Disorders	9.00	3.50	3.50	3.00	1	✓
Neurologic Disorders	6.67	5.00	3.00	4.00	1	✓
Neurologic Disorders	8.00	5.00	2.50	3.00	1	✓
Neurologic Disorders	8.00	4.50	2.00	4.00	1	✓
Neurologic Disorders	8.00	4.50	2.00	4.00	1	✓
Neurologic Disorders	7.00	4.00	5.00	2.50	1	✓
Neurologic Disorders	7.50	4.00	4.50	2.50	1	✓
Neurologic Disorders	7.00	4.00	3.50	4.00	1	✓
Neurologic Disorders	8.00	4.00	3.00	3.50	1	✓
Neurologic Disorders	7.00	4.33	4.67	2.33	1	✓
Neurologic Disorders	6.33	4.33	4.33	3.00	1	✓
Brain Cancers	7.00	4.33	3.33	3.33	1	✓
Neurologic Disorders	8.00	3.00	3.00	4.00	1	✓
Neurologic Disorders	7.33	4.33	4.00	2.00	1	✗
Neurologic Disorders	6.67	3.33	2.33	3.33	1	✗
Neurologic Disorders	7.00	4.67	3.33	2.33	1	✗
Neurologic Disorders	6.33	4.33	3.67	3.00	1	✗
Neurologic Disorders	7.33	4.33	3.67	2.00	1	✗
Neurologic Disorders	7.00	3.67	3.00	3.67	1	✗
Neurologic Disorders	8.33	3.67	3.00	2.33	1	✗
Brain Cancers	9.00	3.33	3.00	2.00	1	✗
Neurologic Disorders	7.00	5.00	2.50	2.50	1	✗
Neurologic Disorders	7.00	5.00	2.50	2.50	1	✗
Neurologic Disorders	6.50	4.50	3.00	3.00	1	✗
Neurologic Disorders	7.00	4.50	2.50	3.00	1	✗
Neurologic Disorders	6.50	4.50	2.00	4.00	1	✗
Neurologic Disorders	7.00	4.50	1.50	4.00	1	✗
Brain Cancers	6.33	4.33	3.33	3.00	1	✗
Brain Cancers	7.00	4.00	3.50	2.50	1	✗
Bone & Cartilage Disorders	7.00	3.50	3.50	3.00	1	✗
Neurologic Disorders	7.00	3.50	3.50	3.00	1	✗
Neurologic Disorders	7.50	3.50	3.50	2.50	1	✗
Neurologic Disorders	8.50	2.50	4.00	2.00	1	✗
Neurologic Disorders	8.00	2.50	3.50	3.00	1	✗
Neurologic Disorders	7.67	3.67	2.67	2.67	1	✗

■ Neuro Topic
 ■ Relevance to human Disease Biology
 ■ Cross Disciplinary & Systems Biology
 ■ Stem Cell or Genetic Research Innovations

Table 4B. DISC4 Cycle 1 Preference Scoring Results (2 of 3)

Disease Areas	Total Score				Invited*	
Neurologic Disorders	6.67	3.67	2.33	4.00	1	×
Neurologic Disorders	7.00	5.00	2.00	2.50	1	×
Neurologic Disorders	7.00	5.00	1.50	3.00	1	×
Neurologic Disorders	7.50	4.00	1.50	3.50	1	×
Neurologic Disorders	8.00	3.50	2.00	3.00	1	×
Neurologic Disorders	7.00	2.50	4.00	3.00	1	×
Neurologic Disorders	7.00	2.50	3.00	4.00	1	×
Eye Vision Disorders, Neurological	8.00	2.00	3.00	3.50	1	×
Brain Cancers	7.00	5.00	3.00	1.00	1	×
Neurologic Disorders	8.00	4.33	2.00	1.67	1	×
Neurologic Disorders	6.67	3.33	2.67	3.33	1	×
Neurologic Disorders	7.00	2.50	3.50	3.00	1	×
Neurologic Disorders	7.00	2.50	3.50	3.00	1	×
Neurologic Disorders	7.00	2.50	3.00	3.50	1	×
Neurologic Disorders	6.50	4.00	3.50	1.50	1	×
Neurologic Disorders	6.50	3.50	3.50	2.00	1	×
Neurologic Disorders	6.50	3.00	3.00	3.00	1	×
Neurologic Disorders	7.33	3.33	1.33	3.33	1, 2	×
Cardiovascular Disorders	7.33	1.67	3.33	3.00	1	×
Neurologic Disorders	6.50	3.50	3.00	2.00	1	×
Neurologic Disorders	7.00	3.50	2.00	2.50	1	×
Neurologic Disorders	7.00	3.50		4.00	1	×
Neurologic Disorders	7.50	3.50		4.00	1	×
Neurologic Disorders	8.00	3.00	1.50	2.50	1	×
Eye Vision Disorders, Neurological	9.00	2.50	1.50	2.00	1	×
Metabolic Disorders	6.50	1.50	4.00	3.00	1	×
Eye Vision Disorders, Neurological	9.00	1.50	1.50	3.00	1	×
Cardiovascular Disorders	7.00	4.50	2.00	1.00	14	×
Neurologic Disorders	7.50	4.00	2.00	1.00	14	×
Eye Vision Disorders, Neurological	6.00	3.50	2.50	2.50	14	×
Eye Vision Disorders, Neurological	6.50	3.50	2.50	2.00	14	×
Brain Cancers	6.50	3.00	3.00	2.00	14	×
Neurologic Disorders	7.50	2.50	2.00	2.50	14	×
Neurologic Disorders	7.50	2.00	2.50	2.50	14	×
Neurologic Disorders	7.00	1.50	4.00	2.00	14	×
Bone & Cartilage Disorders	5.33	3.67	3.00	2.33	14	×
Neurologic Disorders	5.00	3.67	2.67	3.00	14, 4	×
Brain Cancers	7.00	2.67	1.67	3.00	14, 4	×
Neurologic Disorders					14	×
Neurologic Disorders					14	×
Neurologic Disorders					14	×
Neurologic Disorders					14	×
Brain Cancers					14	×
Neurologic Disorders					1	×
Eye Vision Disorders, Neurological					1	×
Neurologic Disorders					1	×

■ Neuro Topic
 ■ Relevance to human Disease Biology
 ■ Cross Disciplinary & Systems Biology
 ■ Stem Cell or Genetic Research Innovations

Table 4B. DISC4 Cycle 1 Preference Scoring Results (3 of 3)

Disease Areas	Total Score	Invited*
Neurologic Disorders	6.00 3.00 2.50 2.00	1
Neurologic Disorders	6.50 3.00 2.00 2.00	1
Neurologic Disorders	5.50 1.50 4.00 2.50	1
Eye Vision Disorders, Neurological	7.00 1.50 3.00 2.00	1
Eye Vision Disorders, Neurological	6.50 3.50 2.00 1.00	1
Cardiovascular Disorders	7.00 3.50 1.00 1.50	1
Brain Cancers	6.00 2.50 2.00 2.50	1
Neurologic Disorders	6.00 2.50 2.00 2.50	1
Neurologic Disorders	7.00 1.50 1.50 3.00	1
Neurologic Disorders	7.00 3.00 1.00 1.67	12
Cancers, Multiple Types Sites	4.50 5.00 3.00	12
Neurologic Disorders	5.50 2.50 2.00 2.50	12
Neurologic Disorders	7.50 1.00 1.00 3.00	12
Other	4.00 5.00 1.67 1.67	12.4
Neurologic Disorders	6.00 3.50 1.50 1.00	12
Neurologic Disorders	6.00 3.00 2.50	12
Neurologic Disorders	5.00 2.50 2.50 2.00	12
Eye Vision Disorders, Neurological	7.00 2.50 2.50	12
Neurologic Disorders	6.50 1.00 2.50 2.00	12
Neurologic Disorders	6.00 4.00 1.50	11
Brain Cancers	6.00 2.50 1.50 1.50	11
Cancers, Multiple Types Sites	5.50 1.50 3.50 1.00	11
Eye Vision Disorders, Neurological	6.50 1.50 1.50 2.00	11
Neurologic Disorders	8.00 1.50 1.50	11
Other	3.50 5.00 2.50	11
Neurologic Disorders	5.50 3.00 2.50	11
Neurologic Disorders	5.00 2.50 1.50 2.00	11
Brain Cancers	5.00 2.50 3.50	11
Other	5.00 4.00 1.50	1
Muscle Disorders	6.50 2.00 1.50	1
Metabolic Disorders	6.00 1.00 1.50 1.50	1
Cardiovascular Disorders	5.50 2.50 1.50	
Cancers, Multiple Types Sites	4.50 2.50 2.50	
Other	4.00 3.00 2.50	
Muscle Disorders	4.00 2.33 1.67 1.33	
Neurologic Disorders	5.00 2.00 2.00	
Neurologic Disorders	3.33 2.67 3.00	
Muscle Disorders	5.00 1.50 2.00	
Metabolic Disorders	2.50 3.50 2.50	
Cardiovascular Disorders	2.00 4.50 2.00	
Brain Cancers	3.00 1.50 3.50	
Cardiovascular Disorders	2.50 2.50 3.00	
Cancers, Multiple Types Sites	3.67 2.00 1.33	
Cancers, Multiple Types Sites	1.00 2.00 2.00	
Cardiovascular Disorders	3.00 1.00	4
Cancers, Multiple Types Sites	2.50 1.50	4

■ Neuro Topic
 ■ Relevance to human Disease Biology
 ■ Cross Disciplinary & Systems Biology
 ■ Stem Cell or Genetic Research Innovations

Appendix B. Portfolio composition across Preclinical and Clinical Programs (PDEV, TRAN1, CLIN1, CLIN2)

Preclinical Portfolio

Preclinical Programs (TRAN1, CLIN1, PDEV):

- Disease and modality diversity are strong
- Portfolio progression to IND clearance has increased significantly
- Progression from IND clearance to active trial execution is increasingly dependent on CIRM funding

CIRM's active portfolio of preclinical stage programs (TRAN1, CLIN1, CLIN2) has significant diversification across modalities and disease areas. The predominant disease areas represented in the active portfolio of preclinical stage programs are neurological disorders, hematology and oncology. The predominant modalities represented in the active portfolio of preclinical stage programs are autologous gene-modified cell therapies, in vivo genetic therapies and allogeneic cell therapies. The primary challenge at this stage is in increasing the likelihood that projects transition successfully from IND clearance to clinical trial launch and patient enrollment.

Clinical Portfolio

CLIN2:

- CLIN2 is increasingly serving as the primary bridge from IND to patient.
- First-in-human (FIH) trials remain the stage where CIRM can most effectively de-risk programs
- Trial activation speed, sponsor durability, capital continuity, and regulatory momentum differentiate advancing programs from stalled ones
- External progression post-FIH has decreased relative to prior years, increasing reliance on CLIN2 funding

At this stage, scientific novelty alone does not determine impact. Execution strength, regulatory trajectory, and financing sustainability are the primary determinants of whether programs ultimately reach patients.

Figure 1. Preclinical & Clinical Portfolio Composition by Modality




Figure 2. Preclinical & Clinical Portfolio Composition by Disease Area




Figure 3. Preclinical & Clinical Portfolio Composition by Rare Disease




Figure 4. Active CLIN2 Trial Phase by Modality




Figure 5. Active CLIN2 Trial Phase by Disease Area





Figure 6. Active CLIN2 Trial Phase by Rare Disease



Appendix C. GWG Review Criteria

Full GWG Review Criteria

The following are the current respective review criteria for DISC4, PDEV and CLIN2 programs utilized by the GWG in evaluating and scoring applications during the Merit Review stage.‡ For the volume control selection step, reviewers focus on the first criterion shown for each funding opportunity, which we collectively refer to as the “scientific value”.

DISC4

The DISC4 funding opportunity supports comprehensive discovery research across a diverse range of diseases and bottlenecks that will accelerate the development of potential therapeutics and biomarkers in regenerative medicine.

The GWG evaluates and scores DISC4 applications based on the following:

- 1. Significance** - *Evaluate the project's significance and potential for impact.*
 - Assess the extent to which a successful project outcome would advance understanding of human disease.
 - Assess the extent to which a successful project outcome would have broader impact, for example through the generation of shareable resources/data.
 - Assess the likelihood that a successful project outcome would rapidly advance to new therapeutic or biomarker development (including consideration of the applicant's vision for progression).
- 2. Innovation** - *Evaluate the project for innovation relative to the current state of research.*
 - Assess the extent to which the project applies novel frameworks to the study of human disease.
 - Assess the extent to which the project cuts across silos or employs a unique synergy of technologies or disciplines to understand human disease.
 - Assess the extent to which the project employs innovative stem cell or genetic research approaches.
- 3. Rationale** - *Evaluate the scientific rationale in the proposal.*
 - Assess the fundamental soundness of the scientific rationale for conducting the proposed research.
 - Assess the extent to which the rationale is supported by the body of available data.
 - Evaluate the scientific rationale for choice of proposed experimental approaches (including non-human models).
 - Assess the extent to which the feasibility of carrying out the proposed experiments is supported by the preliminary data.

‡ Review Criteria shown in this memo are not final. Final criteria will be published in Program Announcements.

4. Plan & Design - *Evaluate the project plan and design.*

- Assess the extent to which the project is planned and designed to give meaningful results.
- Assess the validity of the potential pitfalls identified and alternative approaches presented.
- Evaluate the appropriateness of the budget and timeline for the research proposed.
- Evaluate the appropriateness of leadership, expertise, resources and staffing for the research proposed.
- Assess the effectiveness of the plan for team communications and management of the collaborative effort.

5. Population Impact - *Evaluate the extent to which the project considers the potential impact of successful outcomes across affected populations.*

- Assess how effectively the experimental design accounts for genetic, environmental and other external factors that may influence research findings.
- Assess the extent to which the project may extend or validate the potential applicability of discoveries to additional affected populations or communities.
- Assess how effectively the applicant team’s prior or proposed outreach, partnership, or educational efforts inform study design and enhance the population relevance of potential discoveries.

PDEV

The PDEV funding opportunity supports activities leading to the completion of preclinical development, FDA IND clearance, and clinical trial startup for stem cell-based and genetic therapies. We intend to update the current PDEV GWG review criteria to align with stage-appropriate expectations for patient access planning (criteria to be removed are shown with strike-through, and new criteria are bold).

The GWG evaluates and scores PDEV applications based on the following:

1. Value Proposition - *Evaluate the extent to which the therapy offers a compelling value proposition based on holistic consideration of the following.*

- Assess the therapy’s potential to provide a meaningful and substantial improvement in clinical outcomes for the intended population as compared to therapies currently available or in trials (e.g., efficacy, safety, patient burden).
- Assess the expected impact of addressing the unmet medical need on patients, caregivers, and the healthcare system.
- ~~• Assess the therapy’s potential to be more accessible and affordable compared to available treatments or therapeutics currently in clinical development for the intended patient population and healthcare system.~~
- **Assess whether the applicant has proposed a stage-appropriate strategy for enabling access to the proposed therapy for the intended patient population.**
- Evaluate the feasibility and practicality of the therapy’s uptake by patients, caregivers, and the healthcare system.

2. **Rationale** - *Evaluate the scientific rationale for the proposed therapy and the strength of the supporting data.*
 - Assess the fundamental robustness of the scientific rationale, including justification for the indication, therapeutic approach, and route of administration.
 - Assess the extent to which the rationale is supported by the body of available data. For example, consider whether there is compelling evidence of disease modifying activity in a relevant model.
 - Consider the strengths & limitations of the data presented and/or the models utilized in completed studies.
3. **Project Plan & Design** - *Evaluate the project's plan and design to achieve an active IND.*
 - Evaluate the extent to which the proposed activities are necessary and appropriate to efficiently and effectively progress the project to IND clearance. For example, consider proposed preclinical studies, IND-enabling studies, process and analytical development/testing, clinical protocol drafts and trial startup activities as stage-appropriate.
 - Consider whether the PDEV objective will be achieved within the proposed budget and timeline.
 - Assess the validity of the potential project risks identified along with the mitigation and contingency plans presented.
 - ~~Assess how well the project incorporates stage-appropriate access and affordability planning to support future market access.~~
4. **Project Team and Resources** - *Evaluate the expertise and resources that will be deployed to achieve the project deliverables.*
 - Evaluate the appropriateness of the team's leadership, expertise, and staffing plan to successfully navigate to IND clearance. For example, consider team leadership, expertise and staffing in relevant functional areas such as non-clinical, GMP manufacturing, analytical, regulatory and clinical.
 - Consider whether a robust plan for coordination and execution of the project has been clearly outlined.
 - Assess the extent to which the team has access to all necessary resources and facilities, including manufacturing facilities, to successfully conduct the proposed activities.
 - Consider whether the collective team, including consultants and subcontractors, have a demonstrated track record of supporting stem cell-based and genetic therapy projects to clinical trials.
5. **Population Impact** - *Evaluate the extent to which the project considers the potential impact of the proposed therapy across affected populations.*
 - Evaluate the applicant's understanding and consideration of genetic, environmental and other external factors that may impact on the adoption, effectiveness or safety of the proposed therapy.
 - Assess the appropriateness of the intended clinical study population in the context of the project stage and current knowledge of demographic groups at risk for the target indication.
 - Evaluate the extent to which the applicant's prior or proposed activities incorporate perspectives and experience from patients and individuals affected by the target indication.

CLIN2

The CLIN2 funding opportunity supports projects that will accelerate clinical development of stem cell-based and genetic therapies to late-stage trials by encouraging innovative clinical trial designs, and incentivizing stage-appropriate market access strategies and pre-commercialization activities. We intend to update the current CLIN2 GWG review criteria to align with updates to guiding principles (new criteria are bold).

The GWG evaluates and scores CLIN2 applications based on the following:

1. **Value Proposition** - *Evaluate the extent to which the therapy offers a compelling value proposition based on holistic consideration of the following:*
 - Assess the therapy's potential to provide a meaningful and substantial improvement in clinical outcomes for the intended population as compared to therapies currently available or in trials (e.g., efficacy, safety, patient burden).
 - Assess the expected impact of addressing the unmet medical need on patients, caregivers, and healthcare system.
 - Evaluate the feasibility and practicality of the therapy's uptake by patients, healthcare providers and payors.
 - **Assess whether the applicant has proposed a stage-appropriate strategy for enabling access to the proposed therapy for the intended patient population.**
2. **Rationale** - *Evaluate the scientific rationale for the proposed therapy and the strength of the supporting data*
 - Assess the fundamental robustness of the scientific rationale including justification for the indication, therapeutic approach, regimen and route of administration.
 - Assess the extent to which the rationale for clinical development of the proposed therapy is supported by the body of available data, including compelling evidence of disease modifying activity in relevant disease models and any available clinical trial data generated using the proposed therapeutic approach.
 - Consider the strengths and limitations of the data presented and/or the models utilized in completed studies.
3. **Project Plan and Design** - *Evaluate the project's plan and design.*
 - Evaluate the extent to which the proposed activities are necessary and appropriate to efficiently and effectively drive clinical development of the proposed therapy. For example, the applicant should consider:
 - whether the project will generate data to enable stage appropriate go/no-go decision making for further investment in the approach;
 - the feasibility of achieving timely full enrollment of the trial; and
 - the appropriateness of the manufacturing process, plan and analytical development plans.
 - Consider the whether the project's objective is likely to be achieved within the proposed budget and timeline.
 - Assess the validity of the potential project risks identified and contingency plans presented.

4. **Project Team and Resources** - *Evaluate the expertise and resources that will be deployed to achieve the project deliverables.*
 - Evaluate the appropriateness of the team's leadership, expertise and staffing to successfully complete all aspects of the project.
 - Consider whether a robust plan for coordination and execution of the project has been clearly outlined.
 - Assess the extent to which the team has access to all the necessary resources and facilities, including manufacturing facilities, to successfully conduct the proposed activities.
 - Consider whether the collective team, including consultants and subcontractors, have a demonstrated track record of supporting stem cell-based and genetic therapy projects through clinical trials and/or towards licensure, as stage-appropriate.
5. **Population Impact** - *Evaluate the extent to which the project considers the potential impact of the proposed therapy across affected populations*
 - Evaluate the applicant's understanding and consideration of the affected population for the target indication, including any differences in detection/diagnosis, disease burden, care, and health outcomes across the affected population.
 - Assess the appropriateness of the proposed trial study population in the context of current knowledge of demographic groups at risk for the target indication.
 - Consider the applicant's goals to achieve a comprehensive distribution of subjects appropriate to the proposed indication and whether key criteria to disqualify any at-risk groups are justified.
 - Evaluate the extent to which the applicant's plan for participant outreach, engagement, enrollment and retention addresses key barriers to trial participation by all affected population groups, is well-matched to the proposed study population and is feasible in the proposed time frame.

Appendix D. ARS Memo Template

To: Members of the Application Review Subcommittee
From: CIRM Leadership
Re: CIRM Team Recommendations: [Program Name]
Date: [ARS Meeting Date]

Text in grey boxes or highlights is instructive to the CIRM team or placeholder information that will be replaced with application information in final memos.

Introduction:

The CIRM team’s role during Application Review Subcommittee (ARS) meetings is to assist the ARS in making well-informed funding decisions. The ARS is provided the funding recommendations of the GWG, which include the final scores, assessment against the review criteria, and summary of specific strengths and weaknesses. Beyond these recommendations, the ARS *may* also consider:

1. Programmatic factors
2. Recommendations from the CIRM Team
3. Public comment

This memo details the CIRM Team Recommendations for applications to [Program Name] which the ARS will consider on [Date]. The CIRM Team makes recommendations based on available program budget, GWG score and comments, program Guiding Principles, prior awardee performance (if available), and validated information that comes to CIRM’s attention after the GWG review.

Program Budget Utilization:

Available Program Budget (Annual)	\$XXX M
Budget Utilization – GWG Recommended	\$XX M
Budget Utilization – CIRM Recommended	\$XXM
Remaining Program Budget	\$XX M (GWG Recommended) / \$XX M (CIRM Recommended)

Summary of CIRM Team Recommendations

The CIRM Team will provide a summary table listing application numbers, median GWG score, GWG funding recommendation, and CIRM recommendation for all applications under consideration.

The CIRM Team will provide a brief narrative explaining CIRM recommendations in the context of budget utilization and identify any applications with a Minority Report and for which the CIRM recommendations differs from the GWG recommendation.

Example summary table:

Application	Median GWG Score	GWG Recommendation	CIRM Recommendation
APP-12345	90	Fund	Fund
APP-12346	87	Fund	Fund
APP-12347	85	Fund	Fund
APP-12348*	84	Not Fund	Fund
APP-12349	81	Not Fund	Not Fund
APP-12350	80	Not Fund	Not Fund

Example narrative:

The CIRM team concurs with the GWG recommendations to fund all applications scoring 85 and above. Due to budget availability and based on [GWG merit, strong alignment with program Guiding Principles, and/or other information] CIRM additionally recommends funding APP-12348.

Application Assessments

Application assessments, which include the CIRM team’s analysis of programmatic factors, will be provided for:

- Any application with a Minority Report
- Any application where the CIRM team recommendation differs from the GWG recommendation
- Any application with a score higher than or tied with the lowest-scoring application for which the CIRM team recommendation differs from the GWG recommendation

1. Application number: APP-12348

Title: [insert title]

GWG Outcome:

Median	Mean	High	Low	Scores to fund	Scores not to fund
84					

CIRM Team Recommendation

The CIRM Team recommends APP-12348 for funding based on [insert rationale, which may include alignment with Guiding Principles, GWG sentiment, prior awardee performance, or new material information available to CIRM after GWG]. APP-12348 proposes [insert brief description of application, such as candidate, indication, or other objectives]

Guiding Principles Summary (CLIN2 Example)

Transformative Impact	<i>Comparison to active CIRM awards and external landscape programs within the same indication</i>
Access & Affordability	<i>Summary of access specialist review CIRM knowledge of the modality and route of administration</i>
Disease Representation	<i>Disease area representation and balance in CIRM’s active portfolio</i>